Menu
Valérie Calenda is Managing Partner and Head of Innovation investment activity at Mérieux Equity Partners. She joined Mérieux Equity Partners in January 2010.
Valérie Calenda started her career as research scientist in Hematology and Virology at the Institut National de la Recherche Médicale (INSERM). After collaborating on a French/US research program relating to HIV at Davis University, she joined Transgene S.A, an affiliated company of Institut Mérieux, focusing on gene therapy and immunotherapy. She then led a gene therapy spin-off project in cardio-vascular area before collaborating with a Paris-based seed Venture Capital firm. Valérie also managed several biotech clinical-stage product developments within the infectious diseases and oncology disease areas, from pre-IND to Phase 2. This led her to manage both in-licensing and out-licensing activities, including global license agreement and alliance management with Hoffman La Roche, acquisition of biotech assets in Europe and in the US.
Valérie received her PhD in Pharmacology from the University of Marseille. She holds a degree in Hematology and a B.Sc. in Biochemistry-Immunology from the University of Marseille.
